Astria Therapeutics (NASDAQ:ATXS) Given Overweight Rating at Cantor Fitzgerald

Key Points

• Astria Therapeutics (NASDAQ:ATXS) has received an "overweight" rating from Cantor Fitzgerald, with a price target of $49.00.
• Several analysts have given positive ratings, with a consensus price target of $29.40 and a majority rating of "Buy."
• The company reported earnings of ($0.57) per share, which surpassed expectations of ($0.61) by $0.04 during its last quarterly report.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report)'s stock had its "overweight" rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $49.00 price objective on the biotechnology company's stock.

Several other research firms also recently commented on ATXS. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. HC Wainwright reaffirmed a "buy" rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Finally, JMP Securities upped their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. Based on data from MarketBeat.com, Astria Therapeutics presently has an average rating of "Buy" and a consensus price target of $30.20.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS traded down $0.43 during trading on Wednesday, hitting $7.05. 1,303,719 shares of the company traded hands, compared to its average volume of 348,468. The business's fifty day moving average is $6.77 and its 200 day moving average is $5.76. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92. The firm has a market capitalization of $397.90 million, a price-to-earnings ratio of -3.51 and a beta of 0.42.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.04. On average, analysts predict that Astria Therapeutics will post -1.65 EPS for the current year.

Hedge Funds Weigh In On Astria Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Farther Finance Advisors LLC grew its holdings in shares of Astria Therapeutics by 185.8% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 3,557 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Astria Therapeutics during the 4th quarter valued at $50,000. GAMMA Investing LLC grew its holdings in shares of Astria Therapeutics by 1,127.4% during the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 7,971 shares during the last quarter. Brooklyn Investment Group grew its holdings in shares of Astria Therapeutics by 1,079.6% during the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 7,957 shares during the last quarter. Finally, Corton Capital Inc. bought a new position in shares of Astria Therapeutics during the 1st quarter valued at $72,000. Institutional investors own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.